Cognizant, Boehringer Ingelheim Partners On Unified Cloud Platform To Speed The Delivery Of Life Saving Therapies

Cognizant announced a collaboration with Boehringer Ingelheim, a leading research-driven biopharmaceutical company, to accelerate and improve the quality of therapeutic development.

Cognizant will assist Boehringer Ingelheim in unifying medicinal development processes and data into a connected technology ecosystem, enhancing collaboration across clinical, regulatory, and quality functions.

"Achieving an end-to-end platform to help speed the development of life-changing therapies has been an elusive goal for many organizations, and we're making that vision a reality," Uli Br?dl, senior vice president, global clinical development at Boehringer Ingelheim, said. "Our collaborations with Cognizant and Veeva enable us to advance this critical programme that will improve the lives of patients."

Boehringer Ingelheim's connected ecosystem, dubbed the "One Medicine Platform," is expected to be one of the largest global Veeva technology implementations. This holistic approach is expected to increase interoperability and operational efficiencies by bringing together Boehringer Ingelheim's clinical, regulatory, and quality functions on this unified platform at the same time.

Cognizant began the Boehringer Ingelheim engagement with a business and technology analysis, followed by the development of the programme roadmap and agile methodology for system integration. Cognizant is now implementing services such as programme management, system architecture and design, training, data migration, integration, testing, and validation in collaboration with Veeva.

"Utilizing advanced technologies to improve the quality and delivery of novel medicines is a must for innovative pharmaceutical companies, and Boehringer Ingelheim stands out for their forward thinking in pursuing development of the One Medicine Platform," said Srini Shankar, global head of Cognizant Life Sciences. "Veeva has been recognised as one of the fastest growing life sciences technology companies, and Cognizant is a skilled system integrator with the knowledge required to implement multiple Veeva platforms at the same time." We are proud to be working together to establish new standards for how clinical, regulatory, and quality functions collaborate to help accelerate the delivery of new life-saving therapies."

Everest, an industry analyst firm, named Cognizant one of the leading Veeva Service providers in 2021.

Boehringer Ingelheim is developing life-changing therapies for today and future generations. The company creates value through innovation in areas of high unmet medical need as a leading research-driven biopharmaceutical company.

Cognizant creates cutting-edge businesses. The company assists their clients in modernising technology, reimagining processes, and transforming experiences in order to stay ahead in our rapidly changing world.